Herpes zoster vaccine - Shanghai Institute Of Biological Products
Latest Information Update: 16 Jul 2025
At a glance
- Originator Shanghai Institute of Biological Products
- Class Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes zoster
Most Recent Events
- 10 Apr 2025 Preclinical trials in Herpes zoster (Prevention) in China (IM), before April 2025
- 10 Apr 2025 Shanghai Institute Of Biological Products plans phase I/II trial in Herpes zoster (Prevention) in China (Parenteral) in June 2025 (IM) (NCT06932523)